PolyPeptide Group AG (SWX:PPGN)
43.95
+0.15 (0.34%)
Aug 3, 2026, 4:05 PM CET
PolyPeptide Group AG Revenue
In the year 2025, PolyPeptide Group AG had annual revenue of 391.95M EUR with 15.70% growth. PolyPeptide Group AG had revenue of 224.35M in the half year ending December 31, 2025, with 17.17% growth.
Revenue
391.95M EUR
Revenue Growth
+15.70%
P/S Ratio
3.99
Revenue / Employee
272.19K EUR
Employees
1,440
Market Cap
1.45B CHF
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 391.95M | 53.18M | 15.70% |
| Dec 31, 2024 | 338.77M | 13.92M | 4.28% |
| Dec 31, 2023 | 324.85M | 41.39M | 14.60% |
| Dec 31, 2022 | 283.46M | -2.75M | -0.96% |
| Dec 31, 2021 | 286.22M | 61.41M | 27.31% |
| Dec 31, 2020 | 224.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.96B |
| Novartis AG | 45.81B |
| Lonza Group AG | 6.87B |
| Galderma Group AG | 4.16B |
| Aevis Victoria | 1.04B |
| Tecan Group AG | 882.48M |
| SKAN Group AG | 333.34M |
| Medartis Holding AG | 269.26M |
PolyPeptide Group AG News
- 14 days ago - Samsung Biologics (005940) Proposes $1.8 Billion Acquisition of Polypeptide Group - GuruFocus
- 14 days ago - PolyPeptide Receives CHF 1.46 Bln Samsung Offer, Posts Strong H1 Prelim. Result, Raises Guidance - Nasdaq
- 14 days ago - Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion - GuruFocus
- 14 days ago - Samsung Biologics To Enter Peptide CDMO Market With CHF 1.46 Bln PolyPeptide Acquisition; Stock Down - Nasdaq
- 14 days ago - Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal - CNBC
- 27 days ago - PolyPeptide downgraded to Sector Perform from Outperform at RBC Capital - TheFly
- 6 weeks ago - PolyPeptide price target raised to CHF 38 from CHF 35 at Berenberg - TheFly
- 6 weeks ago - PolyPeptide price target raised to CHF 40 from CHF 33 at Barclays - TheFly